Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Beth O. Van Emburgh, Sebastijan Hobor, Federica Di Nicolantonio, Alberto Bardelli, Sandra Misale, Emily Crowley
Publikováno v:
Clinical Cancer Research. 20:6429-6438
Purpose: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary K
Autor:
Yu Sun, Nengtai Ouyang, Despina Komninou, Gerardo G. Mackenzie, Gang Xie, Basil Rigas, Kvetoslava Vrankova, Liqun Huang
Publikováno v:
Cancer Research. 71:7617-7627
Nonsteroidal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anticancer agents. In this study, we evaluated the chemotherapeutic efficacy of 5 novel
Publikováno v:
Cancer Prevention Research. 4:1655-1664
Colorectal cancer (CRC) is the third most common cause of cancer death in the United States, accounting for approximately 51,000 deaths each year. We have previously shown in vitro chemopreventive effects of mixtures of aspirin, folic acid, and calci
Publikováno v:
Clinical Cancer Research. 11:5248-5256
Purpose: The nonsteroidal antiinflammatory drug sulindac is a promising chemopreventive agent against colon cancer. Here, we address whether sulindac enhances the anticancer effects of the proteasome inhibitor bortezomib (PS-341) in colon cancer cell
Autor:
Michele T. Yip-Schneider, Harikrishna Nakshatri, C. Max Schmidt, Eric A. Wiebke, Christopher Sweeney, Mark S. Marshall
Publikováno v:
Molecular Cancer Therapeutics. 4:587-594
Activation of the transcription factor nuclear factor-kappa B (NF-kappa B) has been implicated in pancreatic tumorigenesis. We evaluated the effect of a novel NF-kappa B inhibitor, parthenolide, a sesquiterpene lactone isolated from the herb feverfew
Autor:
J. Thomas Parsons, Timothy E. Newhook, Jason A. Papin, James M. Lindberg, Sara J. Adair, Lloyd S. Gray, Edik M. Blais, Todd W. Bauer
Publikováno v:
Cancer Research. 74:808-808
Introduction: Survival for patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal and novel therapeutic strategies are needed. Mutations in the KRAS oncogene are important drivers of PDAC progression; however, monotherapies targeting th
Autor:
Peter Besmer, Ferdinando Rossi, Leili Ran, Ping Chi, Yu Chen, Inna Sirota, Devan Murphy, Zhen Cao, Cristina R. Antonescu, John Wongvipat, Shipra Shukla, William D. Tap
Publikováno v:
Cancer Research. 74:3396-3396
Gastrointestinal stromal tumour (GIST) is one of the most common types of human sarcoma and is primarily defined by activating mutations in the KIT or PDGFRA receptor tyrosine kinases. Despite the initial clinical success of imatinib that specificall
Autor:
Mariangela Russo, Carlotta Cancelliere, Alessandra Riggio, Federica Di Nicolantonio, Alberto Bardelli
Publikováno v:
Cancer Research. 74:1843-1843
The monoclonal antibodies cetuximab and panitumumab are approved for the treatment of metastatic colorectal cancers (mCRC). When used as monotherapy, the anti-EGFR antibodies are effective in approximately 15% of patients. It is now well established
Autor:
Christel Larbouret, Vincent Denis, Nadia Vezzio-Vie, Clara Montagut, Pierre Martineau, Maguy Del Rio, Eve Combes, Laetitia K. Linares, Laetitia Marzi, Gaëlle Thomas, Céline Gongora, Mar Iglesias
Publikováno v:
Molecular Cancer Therapeutics. 12:A62-A62
Cetuximab is used in colorectal cancer (CRC), as targeted therapy against the Epithelial Growth Factor receptor (EGFR), in association with chemotherapy (5-FU and irinotecan). Its binding inhibits signalling pathways downstream to the receptor leadin